ArticleNature medicine2025
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.
Abstract readClinical Trial, Phase IMulticenter Study
In one paragraph
Article in Nature medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed.
- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.Nature communications · 2026Trial
- A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.Frontiers in immunology · 2025Trial
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Personalized neoantigen mRNA vaccines for pancreatic cancer: the role of lipid nanoparticle delivery systems.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Review
- Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade.International journal of molecular sciences · 2026Review
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity.Science advances · 2026Article
- From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines.Vaccines · 2026Review
- Targeting lncRNAs to Overcome Cancer Therapy Resistance: Advances in RNA Therapeutics and Delivery Strategies.Cancers · 2026Review
- Universal off-the-shelf TGF-Acta pharmaceutica Sinica. B · 2026Article
- mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models.Nature immunology · 2026Article
- Harnessing Tumor-Specific Transcript Diversity Uncovers a Shared Neoantigen Reservoir for Pancreatic Ductal Adenocarcinoma.MedComm · 2026Article
- Emerging Precision Therapeutic Strategies in Pancreatic Ductal Adenocarcinoma: KRAS Targeting, DDR Vulnerabilities, Immune Redirection, and Tumor Microenvironment Remodeling.Pharmaceutics · 2026Review
- Personalized cancer vaccines: bridging immune-oncology and precision medicine for advanced therapeutics.Signal transduction and targeted therapy · 2026Review
- Review
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- Identification and Validation of the Breast Cancer Diagnostic Biomarker SVEP1 and Its Relationship With CD8 + T Cell Activation Using Bioinformatics and Machine Learning.Applied biochemistry and biotechnology · 2026Article
- Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.Nature communications · 2026Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
80 authors.
Juanita LopezThe Royal Marsden Hospital and the Institute of Cancer Research, Sutton, UK. juanita.lopez@icr.ac.uk.ORCID 0000-0001-8321-4212
Thomas PowlesBarts Cancer Institute, Centre for Experimental Cancer Medicine, Queen Mary University of London, London, UK.ORCID 0000-0001-7760-4724
Fadi BraitehComprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
Lillian L SiuPrincess Margaret Cancer Centre, Toronto, Ontario, Canada.
Patricia LoRussoYale Cancer Center, Yale University, New Haven, CT, USA.ORCID 0000-0001-7144-036X
Claire F FriedmanMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2621-8553
Ani S BalmanoukianThe Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA, USA.
Michael GordonHonorHealth Research Institute, Scottsdale, AZ, USA.
Jeffrey YachninKarolinska University Hospital, Stockholm, Sweden.
Sylvie RotteyDrug Research Unit Ghent, Ghent University Hospital, Ghent, Belgium.
Ioannis KarydisUniversity Hospital Southampton NHS Trust and University of Southampton, Southampton, UK.ORCID 0000-0002-8308-3141
George A FisherDepartment of Medicine (Oncology), Stanford University, Stanford, CA, USA.
Marcus SchmidtUniversity Medical Center Mainz, Mainz, Germany.ORCID 0000-0003-1365-2414
Martin SchulerWest German Cancer Center, Department of Medical Oncology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-2166-3394
Ryan J SullivanMassachusetts General Hospital Cancer Center, Boston, MA, USA.ORCID 0000-0001-5344-6645
Howard A BurrisSarah Cannon Research Institute, Nashville, TN, USA.
Vladimir GalvaoVall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Brian S HenickColumbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA.ORCID 0000-0003-2681-0805
Luc DirixZAS Ziekenhuizen, Oncology Center Antwerp (OCA) Campus Sint-Augustinus, Antwerp, Belgium.
Dirk JaegerNational Center for Tumor Diseases, University Hospital of Heidelberg, Heidelberg, Germany.ORCID 0000-0002-1276-7802
Patrick A OttDana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-4253-943X
Kit Man WongUniversity of Washington School of Medicine, Seattle, WA, USA.
Guy JerusalemCHU Liege and Liege University, Liege, Belgium.
Aglaia SchizaDepartment of Oncology, Uppsala University Hospital, Uppsala, Sweden.
Lawrence FongUCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.ORCID 0000-0002-6428-428X
Neeltje SteeghsNetherlands Cancer Institute, Amsterdam, The Netherlands.ORCID 0000-0003-2989-2279
Rom S LeidnerEarle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA.ORCID 0000-0003-0788-7938
Achim RittmeyerLungenfachklinik Immenhausen, Immenhausen, Germany.
Scott A LaurieThe Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada.
Eelke GortUniversity Medical Center Utrecht, Utrecht, Netherlands.
Raid AljumailyUniversity of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Ignacio MeleroUniversity of Navarra and Instituto de Investigacion Sanitaria de Navarra and CIBERONC, Pamplona, Spain.ORCID 0000-0002-1360-348X
Rachel L SabadoGenentech, Inc., South San Francisco, CA, USA.
Ina RheeGenentech, Inc., South San Francisco, CA, USA.
Michael R MancusoGenentech, Inc., South San Francisco, CA, USA. mancuso.michael@gene.com.ORCID 0009-0007-8023-6759
Lars MullerGenentech, Inc., South San Francisco, CA, USA.
Gregg D FineStork Therapeutics, San Francisco, CA, USA.
Mahesh YadavGenentech, Inc., South San Francisco, CA, USA.
Leesun KimBluejay Therapeutics, San Mateo, CA, USA.
Vincent J P LevequeGenentech, Inc., South San Francisco, CA, USA.
Alberto RobertGenentech, Inc., South San Francisco, CA, USA.
Martine DarwishGenentech, Inc., South San Francisco, CA, USA.
Ting QiGenentech, Inc., South San Francisco, CA, USA.
Jiawen ZhuGenentech, Inc., South San Francisco, CA, USA.
Jingbin ZhangGenentech, Inc., South San Francisco, CA, USA.
Patrick TwomeyGenentech, Inc., South San Francisco, CA, USA.
Gautham K RaoGenentech, Inc., South San Francisco, CA, USA.ORCID 0009-0004-8867-4137
Donald W LowGenentech, Inc., South San Francisco, CA, USA.
Chris PetryGenentech, Inc., South San Francisco, CA, USA.
Amy A LoGenentech, Inc., South San Francisco, CA, USA.ORCID 0000-0002-8614-6734
Jill M SchartnerGenentech, Inc., South San Francisco, CA, USA.
Lélia DelamarreGenentech, Inc., South San Francisco, CA, USA.
Ira MellmanGenentech, Inc., South San Francisco, CA, USA.
Martin LöwerTRON Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Felicitas MüllerBioNTech, Mainz, Germany.
Evelyna DerhovanessianBioNTech, Mainz, Germany.
Andrea CortiniBioNTech, Mainz, Germany.
Luisa ManningBioNTech, Mainz, Germany.
Daniel MaurusBioNTech, Mainz, Germany.
Sebastian BrachtendorfBioNTech, Mainz, Germany.
Verena LörksBioNTech, Mainz, Germany.
Tana OmokokoBioNTech, Mainz, Germany.
Eva GodehardtBioNTech, Mainz, Germany.
Dirk BeckerBioNTech, Mainz, Germany.ORCID 0000-0002-4786-9331
Christine HawnerBioNTech, Mainz, Germany.
Christine WallrappBioNTech, Mainz, Germany.
Christian AlbrechtBioNTech, Mainz, Germany.
Christoph KrönerBioNTech, Mainz, Germany.
Arbel D TadmorBioNTech, Mainz, Germany.
Jan DiekmannBioNTech, Mainz, Germany.
Mathias VormehrBioNTech, Mainz, Germany.
Anette JorkBioNTech, Mainz, Germany.
Anna ParuzynskiBioNTech, Mainz, Germany.
Maren LangBioNTech, Mainz, Germany.ORCID 0000-0003-3578-7053
Jonathon BlakeBioNTech, Mainz, Germany.
Oliver HennigBioNTech, Mainz, Germany.
Andreas N KuhnBioNTech, Mainz, Germany.
Ugur SahinBioNTech, Mainz, Germany.ORCID 0000-0003-0363-1564
Özlem TüreciBioNTech, Mainz, Germany.
D Ross CamidgeDepartment of Medicine-Medical Oncology, University of Colorado Cancer Center, Denver, CO, USA.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748
Abstract
Effective targeting of somatic cancer mutations to enhance the efficacy of cancer immunotherapy requires an individualized approach. Autogene cevumeran is a uridine messenger RNA lipoplex-based individualized neoantigen-specific immunotherapy designed from tumor-specific somatic mutation data obtained from tumor tissue of each individual patient to stimulate T cell responses against up to 20 neoantigens. This ongoing phase 1 study evaluated autogene cevumeran as monotherapy (n = 30) and in combination with atezolizumab (n = 183) in pretreated patients with advanced solid tumors. The primary objective was safety and tolerability; exploratory objectives included evaluation of pharmacokinetics, pharmacodynamics, preliminary antitumor activity and immunogenicity. Non-prespecified interim analysis showed that autogene cevumeran was well tolerated and elicited poly-epitopic neoantigen-specific responses, encompassing CD4
Indexed as
Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNeoplasmsAdultAgedAged, 80 and overAntigens, NeoplasmCD8-Positive T-LymphocytesFemaleHumansImmunotherapyMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntigens, Neoplasmatezolizumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.